[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-335805-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-335805-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","the-origin-of-patient-derived-cancer-organoids-from-pathologically-undiagnosed-specimen-in-patients-with-pancreatobiliary-cancers-research-abstract","The origin of patient-derived cancer organoids from pathologically undiagnosed specimen in patients with pancreatobiliary cancers - Research Abstract","","This study investigates whether patient-derived cancer organoids (PDCOs) can enable precise diagnosis when tissue samples are pathologically negative in pancreatobiliary cancers. Tissue confirmation is challenging due to tumor location and surrounding vessel structure, limiting current methods for obtaining adequate material. Nine samples from four patients were processed using different acquisition methods to establish PDCOs, achieving a 75% success rate. Multi-omics validation assessed representativeness, including tumor panel sequencing, single-cell RNA sequencing, histology, and immunohistochemistry, and evaluated differences between pancreatic and gallbladder cancer cases.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/the-origin-of-patient-derived-cancer-organoids-from-pathologically-undiagnosed-specimen-in-patients-with-pancreatobiliary-cancers-research-abstract/335805/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/the-origin-of-patient-derived-cancer-organoids-from-pathologically-undiagnosed-specimen-in-patients-with-pancreatobiliary-cancers-research-abstract/335805.png","ImageObject",300,407,{"name":42,"@type":43},"Ophelia","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-24","2026-09-21",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",5,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"Why is tissue confirmation difficult in pancreatobiliary cancers?","Question",{"text":63,"@type":64},"Tissue confirmation is often difficult because of the tumor location and the structure of surrounding blood vessels, which complicates obtaining reliable diagnostic material.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How were patient-derived cancer organoids (PDCOs) established in the study?",{"text":68,"@type":64},"Nine samples, including pathologically negative samples, were collected from four patients using different tissue acquisition methods to establish PDCOs, with a reported success rate of 75%.",{"name":70,"@type":61,"acceptedAnswer":71},"What multi-omics methods were used to validate PDCO representativeness?",{"text":72,"@type":64},"The study validated PDCOs using tumor panel sequencing, single-cell RNA sequencing, hematoxylin and eosin histology, and immunohistochemical staining across multiple levels.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},335805,1790216020,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,100,105,110,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":97,"show_sort_weight":98,"slug":99},"Comic",60,"comic",{"id":101,"doc_module":4,"doc_module_name":25,"category_name":102,"show_sort_weight":103,"slug":104},6,"Technology",50,"technology",{"id":106,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},7,"Healthcare",40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},8,30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":55,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":111,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":4},7971461741311,"https://ap-avatar.wpscdn.com/avatar/74000253aff267980c6?x-image-process=image/resize,m_fixed,w_180,h_180&k=1779345379180704826","Cellular Oncology (2025) 48:523–535  \n[https://doi.org/10.1007/s13402-024-01026-5](https://doi.org/10.1007/s13402-024-01026-5)  \nRESEARCH  \nThe origin of patient-derived cancer organoids from pathologically undiagnosed specimen in patients with pancreatobiliary cancers  \nBomi Kim1 · Jiho Park2 · Hee Young Na3 · Sinwoo Park4 · Jeonghwa Jin2 · Kwangrok Jung1 · Jong-Chan Lee1 · Jin-Hyeok Hwang1 · Minseok Seo4 · Jaihwan Kim1  \nAccepted: 3 December 2024 / Published online: 17 December 2024 © The Author(s) 2024  \nAbstract  \nPurpose Tissue confirmation of pancreatobiliary cancer is often difficult because of the location of the tumor and structure of the surrounding blood vessels. Patient-derived cancer organoids (PDCOs) reflect the genomic characteristics of individual cancers. Although diverse attempts to construct PDCOs for various pancreatobiliary cancer models are ongoing, no research results have yet confirmed the possibility of performing a precise diagnosis on PDCOs derived from pathologically negative patient samples.  \nMethods We obtained a total of nine samples, including pathologically negative samples, from four patients (three patients with pancreatic cancer and one patient with gallbladder cancer) using different tissue acquisition methods to establish PDCOs (success rate 75%) .  \nResults We successfully verified whether the constructed PDCOs could represent the tissues of patients with pancreatobiliary cancer at each multi-omics level using tumor panel sequencing, single-cell RNA sequencing, hematoxylin and eosin, and immunohistochemical staining. PDCOs from pathologically negative samples showed expression patterns of malignant ductal cell-related biomarkers similar to those of other pathologically positive samples. Furthermore, the expression patterns at the single-cell level in PDCO from patients ultimately diagnosed with gallbladder cancer after surgery were different from those in patients with pancreatic cancer.  \nConclusion Therefore, our study implicated the potential of PDCOs as diagnostic and research tools, including for case involving limited tissue samples. Based on these results, we anticipate that this could be extended to more advanced studies, such as drug sensitivity testing, through large-scale trials in the near future.  \nKeywords Pancreatic cancer · Gallbladder cancer · Patient derived cancer organoid · Precision therapy · Single-cell RNA sequencing  \nBomi Kim, Jiho Park and Hee Young Na contributed equally to this work.  \n􀀍 Minseok Seo [mins@korea.ac.kr](mins@korea.ac.kr)  \n􀀍 Jaihwan Kim [drjaihwan@snu.ac.kr](drjaihwan@snu.ac.kr)  \n1 Department of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Korea  \n2 Next & Bio Inc., Seoul, Korea  \n3 Department of Pathology, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Korea  \n4 Department of Computer and Information Science, Korea University, Sejong, Korea  \n1 Introduction  \nPancreatic and biliary tract cancer are the representative lethal malignancies [1–3], and sometimes it is difficult to differentiate between the two diseases. For most patients, systemic therapy is required because they were frequently diagnosed at advanced stages [1, 2] . Tissue confirmation is mandatory prior to systemic therapy [4, 5] . However, this is sometimes challenging for pancreatobiliary cancers mainly because of the tumor location and surrounding vessels. Endoscopic ultrasound-guided fine-needle aspiration and biopsy (EUS-FNA/B), and endobiliary biopsy during endoscopic retrograde cholangiopancreatography (ERCP) are the cornerstone techniques for tissue acquisition from pancreatobiliary cancers [6] . The yields for two techniques are  \n524 B. Kim et al.  \nreported tobe 73–89%(EUS-FNA/B) and 29–81%(ERCP), often due to limited sample amounts [7, 8] . Consequently, pathologically negative malignancy results based on EUSFNA/B or ERCP tissue acquisition a","cbCaicbFkgpUueav","https://ap.wps.com/l/cbCaicbFkgpUueav","pdf",6241662,13,"English","# Introduction\n# Methods\n# Results\n# Conclusion\n# Keywords","[{\"question\":\"Why is tissue confirmation difficult in pancreatobiliary cancers?\",\"answer\":\"Tissue confirmation is often difficult because of the tumor location and the structure of surrounding blood vessels, which complicates obtaining reliable diagnostic material.\"},{\"question\":\"How were patient-derived cancer organoids (PDCOs) established in the study?\",\"answer\":\"Nine samples, including pathologically negative samples, were collected from four patients using different tissue acquisition methods to establish PDCOs, with a reported success rate of 75%.\"},{\"question\":\"What multi-omics methods were used to validate PDCO representativeness?\",\"answer\":\"The study validated PDCOs using tumor panel sequencing, single-cell RNA sequencing, hematoxylin and eosin histology, and immunohistochemical staining across multiple levels.\"}]","The origin of patient-derived cancer organoids from pathologically undiagnosed specimen in patients with pancreatobiliary cancers - Research Abstract | PDF",1790012388,33]